Edwin Posadas, MD

The @thenci past meets the present @asco #GU26 Dr. Melissa Abel @melissaabel20 discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh @harpreet_md The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time @theNCI

Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday

Dual masking T-cell engagers do sounds VERY interesting #GU26.

Dr Joshua Watson showing novel biology associated with #livermetastases in #prostatecancer! Proud of his exciting work #GU26

As we get ready for the update on the overall survival in #BRCAAway trial @asco #GU26 It is worth noting the small number of patients that’s crossed over. In that context this data has its limits in comparing combination vs sequence in #ProstateCancer

Great points from Dr. Koontz. Biology should drive decision making #GU26

@AmarUKishan POSEIDON meta-analysis of 6 PhIII RCTs on hormonal therapy (HT) after post-op RT (PORT) in localized #Prostatecancer ➡️ no OS benefit w/HT to PORT & no significant interaction b/t duration of HT & this effect (p-interaction 0.25) for PSA<0.5 #GU26 @OncoAlert

#BRCAaway OS data presented by Dr. Maha Hussein #GU26 @asco Launched prior to large phase 3s in #ProstateCancer Cancer Provocative data but as Dr Hussein acknowledges small numbers in cross over (8 patients) limits ability to truly understand sequencing vs combo

Dr Evan Yu takes stage @asco #GU26 to discuss #Peace3 & #BRCAaway Too often superlatives are thrown around on this app… But do yourself a favor. Watch this whole discussion. One of the more thoughtful takes on modern clinical trial dilemmas in #ProstateCancer Thank you Dr Yu

@katy_beckermann @TNOncology Not sure if you can draw that conclusion given the limited Cross over. Dr Yu’s comment about better studies rings true

🧬 BRCAAway reinforces a key idea in BRCA1/2 or ATM-altered mCRPC: timing matters. Upfront ABI + PARPi outperform a sequential approach in the right genomic subset. mOS 68 mos in combo, 37 mos olaparib, 28 mos abi/pred. #GU26 #ASCOGU26 #ProstateCancer @TNOncology

In Cedars-Sinai Research Tips – Dr. Bin Zheng is senior author on the @NatureComms paper “DHODH Modulates Immune Evasion of Cancer Cells via CDP-Choline Dependent Regulation of Phospholipid Metabolism and Ferroptosis.” <<URL....placeholder>> cedars-sinai.org/newsroom/resea…

It’s always a beautiful day when you can go to clinic and observe a successful #bicalutamide withdrawal maneuver 📉 Yes… even in 2025 🙂 Sometimes less is more in #ProstateCancer (#nmCRPC) Flashback to Dr. Evan Yu & colleagues… tinyurl.com/257dptx2

In Cedars-Sinai Research Tips - Dr. Taylon Silva is first author and Dr. Dolores Di Vizio @doldivizio is corresponding author on the @CellRepMed paper describing an optimized method to improve yields of cancer-specific extracellular vesicles. cedars-sinai.org/newsroom/resea…

Dr. Edwin Posadas @EdwinPosadasMD took part in a Urology Times opinion video “Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive #ProstateCancer Treatment” covering a variety of topics including frailty, molecular testing & sequencing. urologytimes.com/view/subgroup-…

@angela_jia_ great job at the podium today at #ASCO25 You have become a pro!

What did I learn at #ASCO2025 ? 1. Increasing intensity of treatment improves PFS& toxicity- still need OS data for shared decision making 2. Powerful new treatments for #ProstateCancer are coming. get patients on trial 3. Get biomarkers on your #ProstateCancer Thanks everyone!

As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs Did we lower standard to PFS when both agents are approved for mCRPC? 🤔 #ProstateCancer #ASCO25 nature.com/articles/s4158…

Another proud @RadOncUH Chair moment to see our soon to be newest faculty @Soum_Roy_RadOnc being recognized for his statistical brilliance in collaboration with #IRONMAN #ASCO25 @ASCO Way to go! @JasonBrownMDPhD @PBarataMD @jeshoag @LPonsky @GUONCGarciaJA @TedTeknosMD @DanSimonMD

Amazing what STAMPEDE has done for science: the US needs to do something this important for prostate cancer #ASCO25

nice job by @MichaelOng_MD promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25